Neurogenic
Clinical-stage diagnostics company developing sensitive immunoassays to assist in the diagnosis of mental disorders
Startup Pre-Funding Health Tech & Life Sciences Est. 1995
Total Raised
Undisclosed
Pre-Funding
Last Round
Undisclosed
Team
3
1-10 employees
Confidence
87/100
News
1
articles
Patents
1
About
Neurogenic is a clinical-stage diagnostics company developing sensitive immunoassays to assist in the diagnosis of mental disorders. The company has established long-term collaborations with the Weizmann Institute of Science, Rehovot, the Department of Psychiatry, Faculty of Medicine, Tel Aviv University, Tel Aviv, the Beer Yaakov-Ness-Ziona Mental Health Center, Ness Ziona, the Geha Mental Health Center, Petach Tikva, and the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Rabin Medical Center, Petah Tikva, Israel to develop a straightforward, sensitive ELISA-based immunoassay to detect the autoimmune Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients suffering from early-onset symptoms of schizophrenia. Neurogenic is now in the final stages of assay optimization. The company is continuing clinical field testing and validation of the assay.
Classification
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics Devices
Core Technology
BiologicalsMolecules
Target Customer
Healthcare & Life SciencesHealthcareProvidersLaboratories
Business Model
B2B
Tags
immunologymedical-technologiesdiagnosticsblood-testschizophreniamental-healthdoctorsdetectionautoimmune-diseases
News (1)
Mar 11, 2019 · www.synabs.be
growth-positive
Neurogenic and SYnAbs deal for schizophrenia detection
Partners
Details
Product Stage
Clinical Trial
Employees
1-10
Exact Count
2
District
Center District
Founded
1995
Registrar
512103649
Crunchbase
neurogenic
Locations
Ahad Ha'Am St 9, Tel Aviv-Yafo, Israel
Links
Admin
Last Update
Feb 21, 2024
Verified by
Yotam Maman
Claimed
Yes
Missing
video or image, funding rounds, markets, external profiles, not claimed
Team (3)
Yossi Avnat
Director
Yechiel Goldman
Regulatory Writer, Consultant
Mila Shechtman
Senior Scientist